Etoricoxib

Generic Name: Etoricoxib

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₅ClN_₂O_₂S

CAS Number: 202409-33-4

Unique Ingredient Identifier: WRX4NFY03R

Background: Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.

Indication: For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.

Associated Conditions: Ankylosing Spondylitis (AS), Gout, Osteoarthritis (OA), Rheumatoid Arthritis, Moderate Pain

Clinical Trials

Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)

Phase 3

Completed

Conditions: Dysmenorrhea

Interventions: Drug: Etoricoxib
Drug: Ibuprofen
Drug: Placebo to etoricoxib
Drug: Placebo to ibuprofen
Drug: Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg

First Posted Date: 2011-10-31

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 139

Registration Number: NCT01462370

A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)

Phase 4

Withdrawn

Conditions: Osteoarthritis

Interventions: Drug: Etoricoxib
Drug: Placebo for etoricoxib

First Posted Date: 2011-09-05

Last Posted Date: 2022-02-18

Lead Sponsor: Organon and Co

Registration Number: NCT01429168

COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined

Phase 4

Completed

Conditions: Rupture of Anterior Cruciate Ligament

Interventions: Drug: parecoxib, valdecoxib, etoricoxib
Drug: Dexamethasone
Drug: parecoxib, valdecoxib, parecoxib and dexamethasone

First Posted Date: 2011-05-27

Last Posted Date: 2011-05-27

Lead Sponsor: Asker & Baerum Hospital

Target Recruit Count: 93

Registration Number: NCT01361789

Locations: 🇳🇴
Baerum Hospital, Rud, Norway

Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain

Phase 4

Conditions: Low Back Pain

Interventions: Drug: etoricoxib
Drug: oxycodone

First Posted Date: 2011-04-29

Last Posted Date: 2011-04-29

Lead Sponsor: Azienda Sanitaria Locale 4, Teramo

Target Recruit Count: 250

Registration Number: NCT01344720

Locations: 🇮🇹
Unità di riabilitazione neurofisiologica Istituto Scientifico di Riabilitazione di Montescano, Montescano (PV), Pavia, Italy
🇮🇹
Dipartimento di Scienze della Salute Anestesia, Rianimazione e Terapia del dolore - Università degli Studi di L'Aquila Ospedale San Salvatore L'Aquila, L'Aquila, Italy
🇮🇹
Clinica Anestesia e Rianimazione Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Italy

and more 2 locations

Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)

Completed

Conditions: Spondylarthropathies; Spondylitis, Ankylosing

Interventions: Drug: etoricoxib
Drug: Other COX-2 inhibitor
Drug: nsNSAIDs

First Posted Date: 2011-04-01

Last Posted Date: 2024-05-10

Lead Sponsor: Organon and Co

Target Recruit Count: 21108

Registration Number: NCT01327638

Effect of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Selecoxib
Drug: Etoricoxib

First Posted Date: 2011-02-25

Last Posted Date: 2011-07-11

Lead Sponsor: Turku University Hospital

Target Recruit Count: 12

Registration Number: NCT01304069

Locations: 🇫🇮
Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University and Turku University Hospital, Turku, Finland

Effect of an Anti-inflammatory on Tooth Sensitivity Caused by Bleaching

Not Applicable

Completed

Conditions: Color Changes During Tooth Formation

Interventions: Other: Placebo
Drug: Etoricoxib

First Posted Date: 2011-02-23

Last Posted Date: 2017-08-18

Lead Sponsor: Eloisa Andrade de Paula

Target Recruit Count: 30

Registration Number: NCT01300780

Locations: 🇧🇷
Universidade Estadual de Ponta Grossa, Guarapuava, Paraná, Brazil

Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise

Phase 1

Completed

Conditions: Muscle Pain

Interventions: Drug: placebo
Drug: Etoricoxib

First Posted Date: 2011-01-06

Last Posted Date: 2011-11-01

Lead Sponsor: X-pert Med GmbH

Target Recruit Count: 50

Registration Number: NCT01271348

Locations: 🇩🇪
X-pert Med GmbH, Jena, Germany

Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients

Phase 2

Completed

Conditions: HIV

Interventions: Drug: Etoricoxib

First Posted Date: 2011-01-04

Last Posted Date: 2017-05-31

Lead Sponsor: Dag Kvale

Target Recruit Count: 60

Registration Number: NCT01269515

Locations: 🇳🇴
Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway
🇳🇴
The Biotechnology Centre, University of Oslo, Oslo, Norway

Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain

Phase 4

Conditions: Postherpetic Neuralgia
Neuralgia

Interventions: Drug: Placebo
Drug: Etoricoxib

First Posted Date: 2010-12-21

Last Posted Date: 2011-03-23

Lead Sponsor: Analgesic Solutions

Target Recruit Count: 120

Registration Number: NCT01264237

Locations: 🇬🇧
MAC (UK) Neuroscience Ltd, Manchester, United Kingdom
🇬🇧
MAC (UK) Neruoscience Ltd, Liverpool, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy